TY  - JOUR
AU  - Mihaljević, Olgica
AU  - Živančević-Simonović, Snežana
AU  - Lučić-Tomić, Aleksandra
AU  - Živković, Irena
AU  - Minić, Rajna
AU  - Mijatović-Teodorović, Ljiljana
AU  - Jovanović, Zorica
AU  - Anđelković, Marija
AU  - Stanojević-Pirković, Marijana
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/558
AB  - Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p lt 0.001), but positively with FT4 (r=0.696, p  lt  0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps.
AB  - Uvod: Cilj ove studije bio je da uporedimo serumske koncentracije sklerostina kod pacijenata sa disfunkcijom štitaste žlezde u odnosu na eutiroidne kontrolne ispitanike, i da procenimo odnos između sklerostina i markera koštanog metabolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji. Metode: Studijom je obuhvaćeno 30 pacijenata sa disfunkcijom štitaste žlezde (hipotireozom, hipertireozom i supkliničkom hipertireozom) i 10 eutiroidnih kontrola. Slobodni tiroksin (FT4) meren je radioimunološkom metodom, dok je koncentracija tireostimulišućeg hormona (TSH) određivana imunoradiometrijski. Za merenje nivoa sklerostina koristili smo ELISA-test. Metoda elektrohemiluminiscencije primenjena je za merenje koncentracije koštanih markera. Rezultati: Nivo sklerostina bio je značajno niži kod bolesnika sa hipotireozom (p = 0,009) odnosno značajno viši kod bolesnika sa hipertireozom (p = 0,008) u poređenju sa vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti sa hipertireozom su takođe imali statistički značajno viši nivo sklerostina u odnosu na bolesnike sa supkliničkom hipertireozom (p = 0,013). Pokazana je negativna korelacija koncentracije sklerostina i TSH (r = -0,746, p  lt  0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p  lt  0,001) kod pacijenata sa tireoidnom disfunkcijom. Štaviše, sklerostin pozitivno korelira sa koncentracijom osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r = 0,573, p = 0,008) kod ovih pacijenata. Zaključak: Serumski nivoi sklerostina izmenjeni su kod osoba sa disfunkcijom štitaste žlezde. Sklerostin zajedno sa tireoidnim statusom utiče na koštani metabolizam, što se ogleda u njegovoj značajnoj korelaciji sa osteokalcinom i beta-cross-lapsom.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction
T1  - Veza cirkulišućeg nivoa sklerostina sa markerima metabolizma kostiju kod pacijenata sa poremećajem rada štitaste žlezde
EP  - 443
IS  - 4
SP  - 436
VL  - 39
DO  - 10.5937/jomb0-24943
ER  - 

@article{
author = "Mihaljević, Olgica and Živančević-Simonović, Snežana and Lučić-Tomić, Aleksandra and Živković, Irena and Minić, Rajna and Mijatović-Teodorović, Ljiljana and Jovanović, Zorica and Anđelković, Marija and Stanojević-Pirković, Marijana",
year = "2020",
abstract = "Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p lt 0.001), but positively with FT4 (r=0.696, p  lt  0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps., Uvod: Cilj ove studije bio je da uporedimo serumske koncentracije sklerostina kod pacijenata sa disfunkcijom štitaste žlezde u odnosu na eutiroidne kontrolne ispitanike, i da procenimo odnos između sklerostina i markera koštanog metabolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji. Metode: Studijom je obuhvaćeno 30 pacijenata sa disfunkcijom štitaste žlezde (hipotireozom, hipertireozom i supkliničkom hipertireozom) i 10 eutiroidnih kontrola. Slobodni tiroksin (FT4) meren je radioimunološkom metodom, dok je koncentracija tireostimulišućeg hormona (TSH) određivana imunoradiometrijski. Za merenje nivoa sklerostina koristili smo ELISA-test. Metoda elektrohemiluminiscencije primenjena je za merenje koncentracije koštanih markera. Rezultati: Nivo sklerostina bio je značajno niži kod bolesnika sa hipotireozom (p = 0,009) odnosno značajno viši kod bolesnika sa hipertireozom (p = 0,008) u poređenju sa vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti sa hipertireozom su takođe imali statistički značajno viši nivo sklerostina u odnosu na bolesnike sa supkliničkom hipertireozom (p = 0,013). Pokazana je negativna korelacija koncentracije sklerostina i TSH (r = -0,746, p  lt  0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p  lt  0,001) kod pacijenata sa tireoidnom disfunkcijom. Štaviše, sklerostin pozitivno korelira sa koncentracijom osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r = 0,573, p = 0,008) kod ovih pacijenata. Zaključak: Serumski nivoi sklerostina izmenjeni su kod osoba sa disfunkcijom štitaste žlezde. Sklerostin zajedno sa tireoidnim statusom utiče na koštani metabolizam, što se ogleda u njegovoj značajnoj korelaciji sa osteokalcinom i beta-cross-lapsom.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction, Veza cirkulišućeg nivoa sklerostina sa markerima metabolizma kostiju kod pacijenata sa poremećajem rada štitaste žlezde",
pages = "443-436",
number = "4",
volume = "39",
doi = "10.5937/jomb0-24943"
}

Mihaljević, O., Živančević-Simonović, S., Lučić-Tomić, A., Živković, I., Minić, R., Mijatović-Teodorović, L., Jovanović, Z., Anđelković, M.,& Stanojević-Pirković, M.. (2020). The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 39(4), 436-443.
https://doi.org/10.5937/jomb0-24943

Mihaljević O, Živančević-Simonović S, Lučić-Tomić A, Živković I, Minić R, Mijatović-Teodorović L, Jovanović Z, Anđelković M, Stanojević-Pirković M. The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction. in Journal of Medical Biochemistry. 2020;39(4):436-443.
doi:10.5937/jomb0-24943 .

Mihaljević, Olgica, Živančević-Simonović, Snežana, Lučić-Tomić, Aleksandra, Živković, Irena, Minić, Rajna, Mijatović-Teodorović, Ljiljana, Jovanović, Zorica, Anđelković, Marija, Stanojević-Pirković, Marijana, "The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction" in Journal of Medical Biochemistry, 39, no. 4 (2020):436-443,
https://doi.org/10.5937/jomb0-24943 . .

TY  - CONF
AU  - Marinković, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Vukašinović-Vesić, Milica
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2637
UR  - http://intor.torlakinstitut.com/handle/123456789/841
PB  - Lippincott Williams & Wilkins, Philadelphia
C3  - Journal of Clinical Gastroenterology
T1  - The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes
EP  - S228
IS  - Supplement 2
SP  - S227
VL  - 50
UR  - https://hdl.handle.net/21.15107/rcub_intor_841
ER  - 

@conference{
author = "Marinković, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Vukašinović-Vesić, Milica and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Journal of Clinical Gastroenterology",
title = "The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes",
pages = "S228-S227",
number = "Supplement 2",
volume = "50",
url = "https://hdl.handle.net/21.15107/rcub_intor_841"
}

Marinković, D., Minić, R., Dikić, N., Anđelković, M., Vukašinović-Vesić, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes. in Journal of Clinical Gastroenterology
Lippincott Williams & Wilkins, Philadelphia., 50(Supplement 2), S227-S228.
https://hdl.handle.net/21.15107/rcub_intor_841

Marinković D, Minić R, Dikić N, Anđelković M, Vukašinović-Vesić M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes. in Journal of Clinical Gastroenterology. 2016;50(Supplement 2):S227-S228.
https://hdl.handle.net/21.15107/rcub_intor_841 .

Marinković, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Vukašinović-Vesić, Milica, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes" in Journal of Clinical Gastroenterology, 50, no. Supplement 2 (2016):S227-S228,
https://hdl.handle.net/21.15107/rcub_intor_841 .

TY  - JOUR
AU  - Michalickova, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - http://intor.torlakinstitut.com/handle/123456789/607
AB  - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
PB  - Canadian Science Publishing, Ottawa
T2  - Applied Physiology Nutrition and Metabolism
T1  - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
EP  - 789
IS  - 7
SP  - 782
VL  - 41
DO  - 10.1139/apnm-2015-0541
ER  - 

@article{
author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.",
publisher = "Canadian Science Publishing, Ottawa",
journal = "Applied Physiology Nutrition and Metabolism",
title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial",
pages = "789-782",
number = "7",
volume = "41",
doi = "10.1139/apnm-2015-0541"
}

Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism
Canadian Science Publishing, Ottawa., 41(7), 782-789.
https://doi.org/10.1139/apnm-2015-0541

Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789.
doi:10.1139/apnm-2015-0541 .

Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789,
https://doi.org/10.1139/apnm-2015-0541 . .